Donate Now Become a member

Cart (0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

DIA Global Center

Sep 11, 2017 8:15 AM - Sep 12, 2017 3:30 PM

21 Dupont Circle NW, Suite 300, Washington, DC 20036

Navigating Chemistry, Manufacturing, and Controls Through the Drug Development Process

Back to Agenda

Session 27: CMC Considerations in Pediatric Development

Session Chair(s)

Albert S. Yehaskel, MBA

Albert S. Yehaskel, MBA

President and CEO

Refuah Global Pharmaceutical Development, Inc., United States

Pediatric Regulatory Considerations
The Best Pharmaceuticals for Children’s Act (BPCA)
Pediatric Research Equity Act (PREA)
FDA – Pediatric Study Plans
Introduction
Contents of a PSP
Pediatric Formulations Development

Have an account?